CDNA Form 4: 27,453-share RSU grant to director at $0

Rhea-AI Filing Summary

CareDx (CDNA) reported a director equity award. On 10/22/2025, the reporting person acquired 27,453 shares of Common Stock, labeled as an acquisition at a price of $0.

The award is represented by restricted stock units (RSUs) that vest in equal annual installments, with 100% vested on the third anniversary of October 22, 2025, subject to continued service. Each RSU represents the right to receive 1 share of Common Stock upon settlement for no consideration. Following the reported transaction, the reporting person beneficially owned 27,453 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gunasekaran Suresh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,453	$0.00	--

Holdings After Transaction: Common Stock — 27,453 shares (Direct)

Footnotes (1)

1. The reported securities are represented by restricted stock units ("RSUs"), which vest in equal annual installments, such that one-hundred percent of the RSUs will be vested on the third anniversary of October 22, 2025, subject to the Reporting Person's continuous service on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gunasekaran Suresh

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BLVD., 4TH FLOOR

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/22/2025		A		27,453(1)	A	$0(2)	27,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities are represented by restricted stock units ("RSUs"), which vest in equal annual installments, such that one-hundred percent of the RSUs will be vested on the third anniversary of October 22, 2025, subject to the Reporting Person's continuous service on each applicable vesting date.

2. Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

	/s/ Jeffrey Adam Novack, Attorney-in-Fact	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CareDx (CDNA) disclose in this Form 4?

An equity award to a director involving Common Stock associated with RSUs reported as acquired on 10/22/2025.

How many shares were acquired and at what price in the CDNA filing?

The filing shows 27,453 shares of Common Stock acquired at a price of $0.

What is the vesting schedule for the CareDx RSUs?

RSUs vest in equal annual installments, with 100% vested on the third anniversary of October 22, 2025, subject to continuous service.

What does each RSU represent in the CareDx transaction?

Each RSU represents a contingent right to receive 1 share of Common Stock upon settlement for no consideration.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owned 27,453 shares directly following the transaction.

What is the role of the reporting person at CareDx (CDNA)?

The reporting person is disclosed as a Director of CareDx.